Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738620 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4295582 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL2695536 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1 | |
| SCHEMBL3168997 | 0.82 | — | — | |
| SCHEMBL26112782 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL26112778 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL14862483 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL737575 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL9425142 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 | |
| SCHEMBL1827648 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL3L3MBTL1OPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | claimed |
| US-20230041743-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-09 | — | — | US | claimed |
| EP-3532470-B1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| EP-4065586-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-10-05 | — | — | EP | claimed |
| CN-114728987-A | 1, 8-naphthyridin-2-one compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021105072-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-06-03 | — | — | WO | claimed |
| EP-3532470-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | Rigel Pharmaceuticals, Inc. (US) | 2019-09-04 | — | — | EP | claimed |
| WO-2018089199-A1 | OXAZOLE DERIVATIVES FOR USE AS IRAK INHIBITORS AND METHOD FOR THEIR PREPARATION | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | claimed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | claimed |
| CN-101917999-A | Modulation of protein trafficking | FOLDRX PHARMACEUTICALS INC | 2010-12-15 | — | — | CN | claimed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11993594-B2 | IRAK inhibitors and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-110099899-B | Oxazole derivatives useful as IRAK inhibitors and process for their preparation | 里格尔药品股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023196629-A1 | BENZO[H]QUINAZOLINE-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER | Redona Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4218731-A2 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | AbbVie Ireland Unlimited Company (IE) | 2023-08-02 | — | — | EP | disclosed |
| US-5223615-A | Hypotensive agents | SHIONOGI & CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| US-5194608-A | Hypotensive agents; inhibits renin-angiotensin system | SHIONOGI & CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0468641-A2 | Renin inhibiting dipeptide derivatives, their preparation and pharmaceutical preparations containing them | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0371390-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | SMN1; SMN2 4113/4885L3MBTL3 751/4885L3MBTL1 323/4885 |
| US-20230041743-A1 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, NFATC1, NAT1 | SMN1; SMN2 391/4885L3MBTL3 4643/4885L3MBTL1 3844/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | SMN1; SMN2 69/4885L3MBTL3 2754/4885L3MBTL1 1760/4885 |
| US-11993594-B2 | IRAK inhibitors and method for making and using | IRAK1, IRAK2, IRAK3 | SMN1; SMN2 1182/4885L3MBTL3 2060/4885L3MBTL1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.